Norak Biosciences and Development Center for Biotechnology Form Strategic Partnership for GPCR Drug Discovery

Strategic Insights -

Norak Biosciences, a private biotechnology company, has entered into a non-exclusive license agreement with the Development Center for Biotechnology (DCB) in Taiwan, granting DCB access to Norak's proprietary Transfluor technology for high-content screening of G protein-coupled receptor (GPCR) targets. This collaboration aims to leverage DCB's state-of-the-art drug research capabilities and Norak's expertise in GPCR discovery to advance the development of biotechnology and pharmaceutical industries in Taiwan.

Key Takeaways:

  • The partnership will enable DCB to expand its market presence and create new business opportunities in drug discovery services.
  • Norak's Transfluor technology will be incorporated into DCB's current drug research service platforms, providing a comprehensive preclinical drug discovery service.
  • The technology will enable DCB to systematically screen thousands of chemical compounds for GPCR targets, addressing a current gap in Taiwan's drug discovery capabilities.
  • This collaboration marks Norak's entry into the Asian market and positions Transfluor for future growth in the region.
  • The Taiwan government has committed $5 billion in investment for its biotechnology industry over the next five years, further supporting DCB's mission.
  • DCB's partnership with Norak adds to the company's growing portfolio, including a previous agreement with a Japanese pharmaceutical company.

Statistics:

  • $5 billion: The Taiwan government's planned investment in its biotechnology industry over the next five years.
  • 50 years: The length of time pharmaceuticals and scientific communities in Taiwan have been collecting chemical compounds through research efforts in medicinal chemistry research and natural products isolation.
  • 1984: The year DCB was founded as a government-funded, non-profit research organization.
  • 1999: The year Norak licensed Transfluor technology from Duke University Medical School.

Sources:

  • PR Newswire (April 6)
  • Norak Biosciences, Inc.
  • Development Center for Biotechnology (DCB)
  • Taiwan Ministry of Economic Affairs
  • Duke University Medical School
  • Terry E. Willard, Executive Vice President of Norak Biosciences, Inc.
  • Dr. Huang Jui-Lien, CEO of DCB
  • Dr. Roger D. Blevins, President and CEO of Norak